FINWIRES · TerminalLIVE
FINWIRES

Savara Says FDA Extended Review Period for Molgramostim Inhalation Solution Application

By

Savara (SVRA) said late Wednesday the US Food and Drug Administration has extended the review period for molgramostim biologics license application in autoimmune pulmonary alveolar proteinosis, a rare lung disease, by three months.

The new prescription drug user fee act target action date for the inhalation solution is Nov. 22, the company said.

The FDA did not cite any efficacy, safety, or manufacturing concerns, the company said, adding that the FDA determined that the responses to recent information requests represented a significant amendment to the application.

Related Articles

Wire

GitLab Broadens Google Cloud Collaboration to Support AI Agents

GitLab (GTLB) said late Tuesday it expanded its collaboration with Alphabet's (GOOGL, GOOG) Google Cloud, allowing customers to use Google's Vertex AI models to power the GitLab Duo Agent Platform.The integration lets joint customers call Google's AI models directly inside GitLab, with that usage counting toward their existing Google Cloud spending commitments. GitLab said the move pairs Google's model performance with GitLab's built-in security, compliance and audit controls.GitLab shares rose 6.5% in after-hours trading, and Alphabet was little changed.

$GOOG$GOOGL$GTLB
Wire

TeraWulf Preliminary Q1 Revenue Misses Estimates; $800 Million Stock Offering Planned

TeraWulf (WULF) reported preliminary Q1 revenue late Tuesday of $30 million to $35 million and adjusted EBITDA of breakeven to $3 million.Analysts polled by FactSet expect revenue of $37.5 million and EBITDA of $7.6 million.Separately, the company announced an $800 million offering of common shares with underwriters granted a 30-day option to buy up to an additional $120 million in stock.Net proceeds will be used in part to finance a portion of the construction of a data center at its site in Hawesville, Kentucky.TeraWulf shares fell 7.3% in after-hours trading.

$WULF
Wire

Equity Bancshares Q1 Core EPS, Revenue Rise; Shares Fall After Hours

Equity Bancshares (EQBK) reported Q1 core earnings late Tuesday of $1.32 per diluted share, up from $0.90 a year earlier.Analysts polled by FactSet expected $1.16.Revenue in the three months ended March 31, expressed as the sum of net interest income and total noninterest income, rose to $83.2 million from $60.6 million a year earlier.Four analysts surveyed by FactSet expected $82.7 million.The company's shares fell 4.1% in after-hours trading.

$EQBK